Mikhail Blagosklonny is a renowned oncologist who doubles up as a researcher and a professor at Rosewell Park Cancer Institute located in Buffalo, New York. He aims at ensuring that patients around the world access the best treatment irrespective of their economic status. Of specific interest to him is the study of cancer and aging. He is especially interested in the connection between the two. In addition, why the disease is more prevalent in older individuals.
Mikhail continues to conduct research that is significant within the field of oncology. As a professor and influential person in the area, he has been an inspiration to his peers and students who wish to expand on his research.
His topics of interest regarding cancer and aging have attracted attention in the medical field. They also appear in medical journals. In addition to figuring out cancer treatments, he is also interested in figuring out procedures that are effective without being too painful and expensive as is the current situation. He hopes to discover a way through which cancerous cells can be destroyed in the body without interfering with healthy cells. This is crucial to the recovery of the body and mind after a patient has undergone months of cancer treatment.
His immense contribution in the field is unparalleled. As the editor in chief of Oncotarget, Mikhail has conducted and published extensive studies on aging. He is known for his advocacy in the use of Rapamycin, which is a cancer drug, to increase human being’s lifespan. He has also been resourceful in initiating treatment of various ailments using the drug.
Rapamycin is an immunosuppressant, which has displayed lower levels of toxicity to the kidneys and can thus be used in organ transplants as an immunosuppressive drug to lower the risk of rejection of the transplanted organ.
It can be used in treating the hemolytic-uremic syndrome, a disease caused by low platelet count, anemia and kidney failure. It leads to renal failure resulting in long-term dialysis on a patient with the only corrective procedure being a kidney transplant. After treatment, it is possible for the transplanted kidney to contract the same disease. The use of Rapamycin helps to reduce this probability, as it is less toxic to the kidneys. Rapamycin is also used in the coronary stent coating, treatment of Tuberous Sclerosis Complex, and facial angiofibromas.
In ongoing research, Dr. Mikhail has proved that the use of Rapamycin on aging rats enhances their ability to deal with tuberculosis. During initial tests on human beings, it has exhibited immunological rejuvenation when administered to elderly patients. Other areas where the use of the drug has ongoing research include treatment of Alzheimer’s disease, muscular dystrophy, and systematic lupus.
Mikhail Blagosklonny hopes that his findings will inspire others around the world to continue from where he will leave off by conducting future studies. He also anticipates that cancer treatment will no longer be a luxury treatment only accessible to those with money but that it will be a simple and affordable treatment.